

Results of General Meeting

Perth, Australia; 20 April 2022: **Emyria Limited** (ASX:EMD, “Emyria” or the “Company”) advises that a General Meeting of shareholders was held today, 20 April 2022. All resolutions put to the meeting were passed on a Poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that details of the poll results and the proxies received in respect of each resolution are set out below:

Poll results

		For		Against		Abstain
Resolutions		Number	%	Number	%	Number
1A	Ratification of prior issue of Tattarang Shares under Listing Rule 7.1A	90,346,407	99.97	24,750	0.03	82,805
1B	Ratification of prior issue of Tattarang Options under Listing Rule 7.1	90,096,407	99.70	274,750	0.30	82,805
2	Election of Director – Dr. Karen Smith	90,295,462	100.00	2,250	0.00	156,250
3A	Approval of Issue of Tranche 1 Director Shares	40,483,463	99.43	233,650	0.57	411,250
3B	Approval of Issue of Tranche 2 Director Shares	40,484,763	99.43	232,350	0.57	411,250
4	Approval of change of Option Terms	82,838,862	100.00	0	0.00	7,615,100
5	Ratification of previous issue of Corporate Advisory Options	82,826,362	99.74	212,500	0.26	7,415,100

Proxy votes received

Resolutions		For	Against	At Proxy Holders Discretion	Abstain
1A	Ratification of prior issue of Tattarang Shares under Listing Rule 7.1A	89,047,112	24,750	1,199,295	82,805
1B	Ratification of prior issue of Tattarang Options under Listing Rule 7.1	88,797,112	274,750	1,199,295	82,805
2	Election of Director – Dr. Karen Smith	89,036,462	2,250	1,159,000	156,250
3A	Approval of Issue of Tranche 1 Director Shares	39,221,463	233,650	1,162,200	411,250
3B	Approval of Issue of Tranche 2 Director Shares	39,222,763	232,350	1,162,200	411,250
4	Approval of change of Option Terms	81,628,862	0	1,110,000	7,615,000
5	Ratification of previous issue of Corporate Advisory Options	81,616,362	212,500	1,110,000	7,415,100

This announcement has been approved and authorised for release by the Board of Emyria Limited.

For further information:

Dr. Michael Winlo
Managing Director
+61 (0) 8 6559 2800
mwinlo@emyria.com

Lexi O'Halloran
Investor Relations
+61 (0) 404 577 076
investors@emyria.com

Andrew Williams
Media Relations
+61 (0) 412 614 125
awilliams@emyria.com



About Emyria (www.emyria.com)

Emyria Limited develops biopharmaceuticals guided by proprietary Real-World Data collected with patients across its wholly-owned clinical service subsidiary, Emerald Clinics.

Emyria's current clinical development programs are focussed on the registration of proprietary formulations of cannabinoid-based medical treatments (CBMTs) and novel MDMA ('ecstasy') analogues with major global regulators. Emyria's programs target major unmet needs such as mental health disorders and chronic pain.

Emyria's Real World Data (RWD) guides each of Emyria's clinical development programs and care models. Emyria RWD is deep, ethically-sourced clinical evidence gathered with thousands of patients who also receive personalised care at Emerald Clinics.

Emyria is therefore uniquely providing care to patients, generating clinical evidence and advancing multiple proprietary treatment programs towards registration.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.